98 related articles for article (PubMed ID: 17208922)
21. Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma.
Archer CR; Koomoa DL; Mitsunaga EM; Clerc J; Shimizu M; Kaiser M; Schellenberg B; Dudler R; Bachmann AS
Biochem Pharmacol; 2010 Jul; 80(2):170-8. PubMed ID: 20362557
[TBL] [Abstract][Full Text] [Related]
22. Proteasome inhibitors: Dozens of molecules and still counting.
de Bettignies G; Coux O
Biochimie; 2010 Nov; 92(11):1530-45. PubMed ID: 20615448
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel human high-density lipoprotein receptor Up-regulators using a cell-based high-throughput screening assay.
Yang Y; Zhang Z; Jiang W; Gao L; Zhao G; Zheng Z; Wang M; Si S; Hong B
J Biomol Screen; 2007 Mar; 12(2):211-9. PubMed ID: 17259591
[TBL] [Abstract][Full Text] [Related]
24. Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis.
Vandenberghe I; Créancier L; Vispé S; Annereau JP; Barret JM; Pouny I; Samson A; Aussagues Y; Massiot G; Ausseil F; Bailly C; Kruczynski A
Biochem Pharmacol; 2008 Aug; 76(4):453-62. PubMed ID: 18577376
[TBL] [Abstract][Full Text] [Related]
25. Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors.
Mou K; Xu B; Ma C; Yang X; Zou X; Lü Y; Xu P
Bioorg Med Chem Lett; 2008 Mar; 18(6):2198-202. PubMed ID: 18280155
[TBL] [Abstract][Full Text] [Related]
26. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
[TBL] [Abstract][Full Text] [Related]
27. Development of a simple high-throughput screening protocol based on biosynthetic activity of Mycobacterium tuberculosis glutamine synthetase for the identification of novel Inhibitors.
Singh U; Sarkar D
J Biomol Screen; 2006 Dec; 11(8):1035-42. PubMed ID: 16973920
[TBL] [Abstract][Full Text] [Related]
28. Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome.
Mrówka P; Głodkowska E; Młynarczuk-Biały I; Biały L; Kuckelkorn U; Nowis D; Makowski M; Legat M; Gołab J
Acta Biochim Pol; 2008; 55(1):75-84. PubMed ID: 18327303
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates.
Zhu Y; Zhao X; Zhu X; Wu G; Li Y; Ma Y; Yuan Y; Yang J; Hu Y; Ai L; Gao Q
J Med Chem; 2009 Jul; 52(14):4192-9. PubMed ID: 19537716
[TBL] [Abstract][Full Text] [Related]
30. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
31. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors.
Zhu Y; Yao S; Xu B; Ge Z; Cui J; Cheng T; Li R
Bioorg Med Chem; 2009 Oct; 17(19):6851-61. PubMed ID: 19747832
[TBL] [Abstract][Full Text] [Related]
33. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
[TBL] [Abstract][Full Text] [Related]
34. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors.
Sprangers R; Li X; Mao X; Rubinstein JL; Schimmer AD; Kay LE
Biochemistry; 2008 Jul; 47(26):6727-34. PubMed ID: 18540636
[TBL] [Abstract][Full Text] [Related]
35. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibition as a novel therapeutic target in human cancer.
Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
[TBL] [Abstract][Full Text] [Related]
37. Homogeneous and nonradioactive high-throughput screening platform for the characterization of kinase inhibitors in cell lysates.
Guenat S; Rouleau N; Bielmann C; Bedard J; Maurer F; Allaman-Pillet N; Nicod P; Bielefeld-Sévigny M; Beckmann JS; Bonny C; Bossé R; Roduit R
J Biomol Screen; 2006 Dec; 11(8):1015-26. PubMed ID: 17092917
[TBL] [Abstract][Full Text] [Related]
38. In vivo imaging, tracking, and targeting of cancer stem cells.
Vlashi E; Kim K; Lagadec C; Donna LD; McDonald JT; Eghbali M; Sayre JW; Stefani E; McBride W; Pajonk F
J Natl Cancer Inst; 2009 Mar; 101(5):350-9. PubMed ID: 19244169
[TBL] [Abstract][Full Text] [Related]
39. Identification of chemoradiation-resistant osteosarcoma stem cells using an imaging system for proteasome activity.
Tamari K; Hayashi K; Ishii H; Kano Y; Konno M; Kawamoto K; Nishida N; Koseki J; Fukusumi T; Hasegawa S; Ogawa H; Hamabe A; Miyo M; Noguchi K; Seo Y; Doki Y; Mori M; Ogawa K
Int J Oncol; 2014 Dec; 45(6):2349-54. PubMed ID: 25269626
[TBL] [Abstract][Full Text] [Related]
40. High-throughput mass spectrometry screening for inhibitors of phosphatidylserine decarboxylase.
Forbes CD; Toth JG; Ozbal CC; Lamarr WA; Pendleton JA; Rocks S; Gedrich RW; Osterman DG; Landro JA; Lumb KJ
J Biomol Screen; 2007 Aug; 12(5):628-34. PubMed ID: 17478478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
